I believe that if the company's strategy of bringing the psoriasis cream and the sublingual tablet into the marketplace, even in a limited number of countries this year is successful, a market cap of a billion or more by the end of the year is very probable. That's roughly a ten banger from where we are today.
Sales of these products at first might be slow, but if they're all the company believes they are, they'll rise quite rapidly. Where would we be by the end of 2018 if the combined earnings for that year are $.5 billion. P.E.'s typically run between ten and thirty times earnings, so if we assume our share count increases to 150 million, that would be $3.33 a share in earnings. At a P/E of ten that's $33 a share, at thirty it's $100. I'm not saying this will happen, but I believe the potential is there. Even if my figures are 50% high, would anyone regret a share price between $17 and $50.
In today's world I can't imagine these products being available for years and not selling billions of dollars worth of products. Unless the company abandon's it's current plan for marketing the product, they should be making earnings that go into the billions in a matter of years. I don't care how you do the math, in time the share price should go into triple digits.
Gary
News 
Market Data 
Discover 
